Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has allotted 44,000 equity shares of face value Rs. 10 each to three non-promoter allottees upon conversion of warrants. The conversion follows the payment of the balance consideration by warrant holders and is pursuant to shareholder approval from an EGM held on October 22, 2025. The warrants were initially allotted on December 29, 2025. After a 1:2 bonus issue, 14,667 warrants were converted into 44,000 equity shares. The issue price per warrant was Rs. 1,250, with 25% payable upfront. The newly allotted shares will rank pari passu with existing equity shares.

Fredun Pharmaceuticals Ltd has allotted 44,000 equity shares to non-promoter allottees following the conversion of 14,667 warrants. This conversion was made possible after the company's 1:2 bonus issue, which proportionately adjusted the entitlement of outstanding warrants. The warrants were initially allotted on December 29, 2025, on a preferential basis. The conversion exercise, completed on October 23, 2026, involved the payment of the balance consideration by the warrant holders. The newly allotted shares rank pari passu with existing equity shares.

Fredun Pharmaceuticals is transforming into a brand-led healthcare platform, with H1 FY27 seeing expansion in pet healthcare, premium wellness, and global markets. Key initiatives include acquiring a 26% stake in Goodman Vetcare for ₹300 crore, expanding its veterinary retail presence. They also acquired Furlicks, an oral-strip pet-wellness brand, planning to increase SKUs from 6 to 22. WAGR, a tech-enabled pet-parenting platform, is being developed as India's largest pet-care ecosystem. The company aims to transition from OEM to a 100% branded portfolio by 2029, targeting a doubling of revenue and profitability in 3-4 years. Manufacturing capacity is also being expanded with a new utility block at Palghar. Fredun also allotted bonus equity shares and further shares post-warrant conversion.

Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares of face value Rs. 10 each upon the conversion of 60,800 warrants. This follows the payment of the balance consideration by warrant holders. The warrants were initially allotted on a preferential basis on December 29, 2025, pursuant to shareholder approval. The allotment of equity shares, made in dematerialized form, ranks pari passu with existing shares. The conversion and allotment were adjusted for a recent 1:2 bonus issue, impacting the number of shares per warrant and the exercise price.

Fredun Pharmaceuticals Ltd's Board of Directors, in a meeting held on October 03, 2026, allotted 1,82,400 equity shares of face value Rs. 10/- each to warrant holders. This allotment follows the conversion of 60,800 warrants, for which the warrant holders had paid the balance consideration and exercised their rights. These warrants were originally allotted on a preferential basis on December 29, 2025. The entitlement of these warrants was proportionately adjusted due to a 1:2 bonus issue by the company, leading to each warrant being exercisable into three equity shares. The newly allotted equity shares will rank pari passu with the existing equity shares.

Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees following the conversion of 60,800 warrants. This conversion was made possible after a 1:2 bonus issue adjusted the warrant entitlements. The allotment follows the payment of the balance consideration by warrant holders. The new shares, with a face value of Rs. 10 each, will rank pari passu with existing equity shares.

Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares of face value Rs. 10/- each pursuant to the conversion of 60,800 warrants. This follows the payment of the balance consideration by warrant holders and approval from shareholders in an EGM held on October 22, 2025. The warrants were initially allotted on a preferential basis on December 29, 2025. The conversion and allotment were approved by the Board of Directors in a meeting held on October 03, 2026. The issue price per warrant was Rs. 1,250/-, with 25% payable upfront. Post a 1:2 bonus issue, the entitlement was adjusted, resulting in three equity shares per warrant upon payment of the balance consideration. The newly allotted shares will rank pari passu with existing equity shares.

Fredun Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The closure is effective from Thursday, October 1, 2026, and will remain in effect until 48 hours after the Board Meeting. This meeting will be held to consider, approve, and declare the unaudited financial results for the quarter and half-year ended September 30, 2026. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

Fredun Pharmaceuticals Ltd announced the allotment of 3,61,599 equity shares following the conversion of 1,20,533 warrants. This conversion was approved by shareholders in an EGM on October 22, 2025, with warrants initially allotted on December 29, 2025. The company's Board of Directors approved the allotment on September 16, 2026, after warrant holders paid the balance consideration. The equity shares, with a face value of Rs. 10 each, rank pari passu with existing shares. The conversion and allotment were adjusted for a recent 1:2 bonus issue.

Fredun Pharmaceuticals Ltd's Board of Directors, in a meeting held on September 16, 2026, has allotted 3,61,599 Equity Shares of face value ₹10 each. This allotment is a result of the conversion of 1,20,533 convertible warrants. These warrants were initially allotted on a preferential basis on December 29, 2025, following shareholder approval. The warrant holders paid the balance consideration and exercised their rights for conversion. The entitlement for conversion was adjusted after the company's 1:2 bonus issue, leading to each warrant converting into three equity shares. The newly allotted shares will be in dematerialized form and rank pari passu with existing equity shares.